Drug Profile
Research programme: skin disorder therapeutics - Afecta Pharmaceuticals
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Afecta Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action CCR2 receptor antagonists; Chemokine CCL2 inhibitors; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Skin-disorders in USA